Company / Current Liabilities
Cogent Biosciences, Inc. Current Liabilities History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Liabilities
$64.0M
FY2025
5-year range
$17.1M / $64.0M
FY2021-FY2025
Trend
+14.8%
vs FY2024
Sector context
#124 of 213
Health Care
What the data says
At $64M, Cogent Biosciences, Inc.'s current liabilities ranks #90 of 213 in the Health Care sector. Current Liabilities has increased for 5 consecutive years, from $13M in FY2020 to $64M in FY2025.
Based on SEC 10-K filings.
$64M in FY2025 with a 5-year CAGR of +37.3%.
Increased from $38M to $64M over the past 2 years.
Health Care sector context is included.
Current Liabilities over time
Growth rates
- 3-Year CAGR
- +33.6%
- 5-Year CAGR
- +37.3%
- 10-Year CAGR
- -
Sector benchmark
#90 of 213 in Health CareTop 42% of 213This company $64.0M Sector average $1.6B
▼
-96.0% below sector average
Key checks
Key Insights
- Cogent Biosciences, Inc.'s current liabilities has grown for 5 consecutive years.
- 5-year CAGR of +37.3%, indicating consistent growth.
- In FY2025, current liabilities increased 14.8% year-over-year.
- Ranks #124 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 0.43 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current LiabilitiesValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $64.0M | +14.8% |
| FY2024 | $55.7M | +46.0% |
| FY2023 | $38.2M | +42.2% |
| FY2022 | $26.8M | +57.2% |
| FY2021 | $17.1M | +30.4% |
| FY2020 | $13.1M | -1.2% |
| FY2019 | $13.2M | -46.9% |
| FY2018 | $24.9M | +122.9% |
| FY2017 | $11.2M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026